On 21 November 2022, the minister of health tabled the 2021 Annual Report of the Patented Medicine Prices Review Board (PMPRB). The report includes information on the PMBRB's regulatory activities, pharmaceutical sales and price trends, and an analysis of the research and development expenditures. According to the report, in 2021, sales of patented medicines in Canada decreased by 1.7% from the previous year for a total of C$17.4 billion, and the national average transaction price for patented medicines increased by 0.4%, while the consumer price index increased by 3.4%.

For further information on this topic please contact Urszula Wojtyra at Smart & Biggar by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar website can be accessed at www.smartbiggar.ca.